CN1170542C - 奥卡西平包膜片剂 - Google Patents

奥卡西平包膜片剂 Download PDF

Info

Publication number
CN1170542C
CN1170542C CNB988024977A CN98802497A CN1170542C CN 1170542 C CN1170542 C CN 1170542C CN B988024977 A CNB988024977 A CN B988024977A CN 98802497 A CN98802497 A CN 98802497A CN 1170542 C CN1170542 C CN 1170542C
Authority
CN
China
Prior art keywords
oxcarbazepine
film
median particle
particle diameter
sieves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988024977A
Other languages
English (en)
Chinese (zh)
Other versions
CN1247471A (zh
Inventor
B��³�����
B·施鲁特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1170542(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1247471A publication Critical patent/CN1247471A/zh
Application granted granted Critical
Publication of CN1170542C publication Critical patent/CN1170542C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNB988024977A 1997-02-14 1998-02-12 奥卡西平包膜片剂 Expired - Fee Related CN1170542C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH33197 1997-02-14
CH331/1997 1997-02-14
CH331/97 1997-02-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200410075200XA Division CN1626093A (zh) 1997-02-14 1998-02-12 奥卡西平包膜片剂

Publications (2)

Publication Number Publication Date
CN1247471A CN1247471A (zh) 2000-03-15
CN1170542C true CN1170542C (zh) 2004-10-13

Family

ID=4184588

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988024977A Expired - Fee Related CN1170542C (zh) 1997-02-14 1998-02-12 奥卡西平包膜片剂
CNA200410075200XA Pending CN1626093A (zh) 1997-02-14 1998-02-12 奥卡西平包膜片剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200410075200XA Pending CN1626093A (zh) 1997-02-14 1998-02-12 奥卡西平包膜片剂

Country Status (31)

Country Link
US (2) US20070036863A1 (cg-RX-API-DMAC7.html)
EP (1) EP0966287B1 (cg-RX-API-DMAC7.html)
JP (3) JP2000511935A (cg-RX-API-DMAC7.html)
KR (3) KR19980071337A (cg-RX-API-DMAC7.html)
CN (2) CN1170542C (cg-RX-API-DMAC7.html)
AR (1) AR011142A1 (cg-RX-API-DMAC7.html)
AT (1) ATE239481T1 (cg-RX-API-DMAC7.html)
AU (1) AU738030B2 (cg-RX-API-DMAC7.html)
BR (1) BR9807368A (cg-RX-API-DMAC7.html)
CA (1) CA2277791C (cg-RX-API-DMAC7.html)
CO (1) CO4920215A1 (cg-RX-API-DMAC7.html)
CY (1) CY2480B1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298840B6 (cg-RX-API-DMAC7.html)
DE (1) DE69814367T2 (cg-RX-API-DMAC7.html)
DK (1) DK0966287T3 (cg-RX-API-DMAC7.html)
ES (1) ES2199422T3 (cg-RX-API-DMAC7.html)
HU (1) HU227807B1 (cg-RX-API-DMAC7.html)
ID (1) ID22348A (cg-RX-API-DMAC7.html)
MY (1) MY117582A (cg-RX-API-DMAC7.html)
NO (1) NO327486B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336946A (cg-RX-API-DMAC7.html)
PE (1) PE58999A1 (cg-RX-API-DMAC7.html)
PL (1) PL193332B1 (cg-RX-API-DMAC7.html)
PT (1) PT966287E (cg-RX-API-DMAC7.html)
RU (1) RU2201218C2 (cg-RX-API-DMAC7.html)
SK (1) SK284503B6 (cg-RX-API-DMAC7.html)
TR (1) TR199901804T2 (cg-RX-API-DMAC7.html)
TW (1) TW529957B (cg-RX-API-DMAC7.html)
UY (1) UY24888A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998035681A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA981205B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
NZ532707A (en) 2001-12-21 2006-07-28 Pfizer Prod Inc Directly compressible formulations of azithromycin
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
WO2005020968A2 (en) 2003-09-03 2005-03-10 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
US9034381B2 (en) 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
CA2634879A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US20070178164A1 (en) * 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007121523A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
US20090196923A1 (en) 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
JP2010513324A (ja) 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
EP2146699A2 (en) * 2007-05-23 2010-01-27 Ratiopharm GmbH Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN103735527B (zh) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (ja) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd コ−テイング剤組成物
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
HK1024423A1 (en) 2000-10-13
CA2277791C (en) 2008-11-18
AR011142A1 (es) 2000-08-02
AU6622298A (en) 1998-09-08
KR20090037873A (ko) 2009-04-16
JP2000511935A (ja) 2000-09-12
MY117582A (en) 2004-07-31
CO4920215A1 (es) 2000-05-29
DE69814367D1 (de) 2003-06-12
PL334959A1 (en) 2000-03-27
PL193332B1 (pl) 2007-02-28
KR20120079826A (ko) 2012-07-13
CY2480B1 (en) 2005-06-03
ZA981205B (en) 1998-08-14
CN1626093A (zh) 2005-06-15
ID22348A (id) 1999-09-30
HUP0000886A2 (hu) 2000-09-28
RU2201218C2 (ru) 2003-03-27
TR199901804T2 (xx) 1999-09-21
SK109899A3 (en) 2000-03-13
ATE239481T1 (de) 2003-05-15
CA2277791A1 (en) 1998-08-20
WO1998035681A1 (en) 1998-08-20
NO327486B1 (no) 2009-07-13
NO993919L (no) 1999-08-13
HU227807B1 (en) 2012-03-28
JP2006077029A (ja) 2006-03-23
DE69814367T2 (de) 2004-02-26
DK0966287T3 (da) 2003-08-25
KR19980071337A (ko) 1998-10-26
CZ298840B6 (cs) 2008-02-20
ES2199422T3 (es) 2004-02-16
UY24888A1 (es) 2000-12-29
CZ287999A3 (cs) 1999-11-17
US20070036863A1 (en) 2007-02-15
TW529957B (en) 2003-05-01
SK284503B6 (sk) 2005-05-05
HUP0000886A3 (en) 2002-10-28
US20080014269A1 (en) 2008-01-17
JP2010132694A (ja) 2010-06-17
PT966287E (pt) 2003-09-30
NZ336946A (en) 2001-02-23
CN1247471A (zh) 2000-03-15
AU738030B2 (en) 2001-09-06
EP0966287A1 (en) 1999-12-29
BR9807368A (pt) 2000-03-14
EP0966287B1 (en) 2003-05-07
PE58999A1 (es) 1999-06-25
NO993919D0 (no) 1999-08-13

Similar Documents

Publication Publication Date Title
AU738030B2 (en) Oxacarbazepine film-coated tablets
AU777705B2 (en) Pharmaceutical compositions
AU2019280026B2 (en) Galenic formulations of organic compounds
JP3636380B2 (ja) 二重層オキカルバゼピン錠剤
US7037525B2 (en) Oxacarbazepine film-coated tablets
CN102970982B (zh) 肠溶片剂
JP2006501274A (ja) オキシカルバゼピンおよびその誘導体の改良放出製剤
US10722471B2 (en) Galenic formulations of organic compounds
HK1024423B (en) Oxacarbazepine film-coated tablets
NZ509391A (en) Oxacarbazepine film-coated tablets further comprising a hydrophobic permeable outer coating containing iron oxide from 0.3 to 0.9 mg per tablet
RU2773029C2 (ru) Галеновые композиции органических соединений
MXPA99007514A (en) Oxacarbazepine film-coated tablets

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041013

Termination date: 20140212